Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Cash from Investing Activities (2016 - 2025)

Perspective Therapeutics' Cash from Investing Activities history spans 16 years, with the latest figure at $14.0 million for Q3 2025.

  • For Q3 2025, Cash from Investing Activities rose 147.05% year-over-year to $14.0 million; the TTM value through Sep 2025 reached -$125.9 million, down 56.57%, while the annual FY2024 figure was -$218.9 million, 998.25% down from the prior year.
  • Cash from Investing Activities for Q3 2025 was $14.0 million at Perspective Therapeutics, up from $4.3 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $35.2 million in Q4 2021 and bottomed at -$138.6 million in Q4 2024.
  • The 5-year median for Cash from Investing Activities is -$149000.0 (2022), against an average of -$11.1 million.
  • The largest annual shift saw Cash from Investing Activities skyrocketed 97261.54% in 2023 before it plummeted 155632.58% in 2024.
  • A 5-year view of Cash from Investing Activities shows it stood at $35.2 million in 2021, then plummeted by 181.98% to -$28.8 million in 2022, then soared by 99.69% to -$89000.0 in 2023, then tumbled by 155632.58% to -$138.6 million in 2024, then surged by 110.1% to $14.0 million in 2025.
  • Per Business Quant, the three most recent readings for CATX's Cash from Investing Activities are $14.0 million (Q3 2025), $4.3 million (Q2 2025), and -$5.6 million (Q1 2025).